Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[22/11/2022]

UCB : UCB Media Room: UCB Submits Response to FDA Complete Response Letter for Bimekizumab

https://mb.cision.com/Public/18595/3670611/b35d1142fa4a1983_800x800ar.png UCB Submits Response to FDA Complete Response Letter for Bimekizumab Brussels Belgium, 22nd November 2022 =E2=80=93 18:30 CET =E2=80=93 UCB,= a global biopharmaceutical company, today announced that it has resubmitte= d the Biologics License Application BLA to the U.S. Food and Drug Adminis= tration FDA for... See more
 
UCB [BE0003739530/UCB]   
[14/11/2022]

UCB : UCB Media Room: U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

https://mb.cision.com/Public/18595/3666193/9cece37fb36d9bab_800x800ar.png UCB announces U.S. FDA acceptance of new drug application and EMA MAA va= lidation for zilucoplan for the treatment of generalized myasthenia gravis = in adult patients =C2=B7 New drug application NDA for zilucoplan seeks approval for the tre= atment of generalized myasthenia gravis gMG in adult patients who are... See more
 
UCB [BE0003739530/UCB]   
[10/11/2022]

UCB : UCB Media Room: bimekizumab data at ACR 2022

https://mb.cision.com/Public/18595/3664497/8a15d6f32cb1113b_800x800ar.png Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phas= e 3 Studies in Psoriatic Arthritis, NonRadiographic Axial Spondyloarthriti= s and Ankylosing Spondylitis =C2=B7 New latebreaking 52week data from Phase 3 bimekizumab investigatio= nal studies in psoriatic arthritis and across the spectrum... See more
 
UCB [BE0003739530/UCB]   
[08/11/2022]

UCB : UCB Media Room: UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

https://mb.cision.com/Public/18595/3663475/a3ca183b23c7b65b_800x800ar.png UCB Reinforces Commitment to Rheumatology with 15 Abstracts including Ne= w LateBreaking Data at ACR Convergence 2022 =C2=B7 Latebreaking 52week data on investigational bimekizumab in the tre= atment of adults with active psoriatic arthritis and active axial spondyloa= rthritis to be presented =C2=B7 New data... See more
 
UCB [BE0003739530/UCB]   
[27/09/2022]

UCB : FINTEPLA®▼ (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

https://mb.cision.com/Public/18595/3636902/999776931e930491_800x800ar.png FINTEPLA^=C2=AE=E2=96=BC fenfluramine Approved in Japan for the Treatm= ent of Seizures Associated with Dravet Syndrome =C2=B7 Approval supported by clinical trial data that showed when added to = existing treatment regimens, fenfluramine significantly reduced monthly con= vulsive seizure frequency compared to... See more